Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ABBV-990 in Healthy Volunteers
NCT05475821Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-990 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events (AEs) at 30 days, Maximum Observed Plasma Concentration at 5 days and 4 more. Started Jul 2022; status: terminated.
02
Drugs
ABBV-990
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05475821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475821.